Hungarian government bill 19/2021. (I. 28.), and the corresponding permission of the Hungarian FDA (OGYÉI/5142-2/2021).
National Institute of Pharmacy and Nutrition. Alkalmazás előírás, SARS-CoV-2 vakcina (VeroCell), inaktivált. https://www.ogyei.gov.hu/dynamic/sinopharm_vakcina_taj_szakembereknek.pdf Accessed 10 June 2021.
European Centre for Disease Prevention and Control. COVID-19 vaccine tracker. https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html. Accessed 21 June 2021.
Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–9.
Mallapaty S. Scientists zero in on long-sought marker of COVID-vaccine efficacy. Nature. 2021. https://doi.org/10.1038/d41586-021-01372-6.
Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384:533–40.
Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181:672.
Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021. https://doi.org/10.1016/j.vaccine.2021.05.063.
Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020. https://doi.org/10.1128/JCM.02107-20.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. https://doi.org/10.1038/s41591-021-01377-8.
Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397:1459–69.
Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40.
Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9:712–20.
Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61:927–34.
Bungener L, Geeraedts F, ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008;26:2350–9.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021. https://doi.org/10.1001/jama.2021.8565.
Choi WS, Cheong HJ. COVID-19 vaccination for people with comorbidities. Infect Chemother. 2021;53:155.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.
US Food and Drug Administration. Vaccines and related biological products advisory committee meeting December 10, 2020. FDA briefing document. Pfizer-BioNTech COVID-19 vaccine. https://www.fda.gov/media/144245/download. Accessed 27 June 2021.
Lord JM. The effect of ageing of the immune system on vaccination responses. Hum Vaccines Immunother. 2013;9:1364–7.
Van Der Meeren O, Crasta P, Cheuvart B, De Ridder M. Characterization of an age-response relationship to GSK’s recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum Vaccines Immunother. 2015;11:1726–9.
McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012–2013: variable protection by age and virus type. J Infect Dis. 2015;211:1529–40.
Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417–22.
Stark K, Günther M, Neuhaus R, Reinke P, Schröder K, Linnig S, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999;180:2014–7.
Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccines Immunother. 2018;14:1311–22.
Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75:435–8.
McGill COVID19 Vaccine Tracker Team. COVID19 vaccine tracker: Sinopharm (Beijing): BBIBP-CorV. https://covid19.trackvaccines.org/vaccines/5/. Accessed 28 June 2021.
World Health Organization. WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations. Accessed 7 May 2021.
Ocmant A, Roisin S, De Meuter R, Brauner J. Clinical performance of the Advia Centaur anti-SARS-CoV-2 chemiluminescent immunoassay related to antibody kinetics. J Med Virol. 2021;93:2583–4.
Müller L, Ostermann PN, Walker A, Wienemann T, Mertens A, Adams O, et al. Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. Eur J Clin Microbiol Infect Dis. 2021;40:1063–71.
Shi AC, Ren P. SARS-CoV-2 serology testing: progress and challenges. J Immunol Methods. 2021;494:113060.
Centers for Disease Control and Prevention (CDC). Interim guidelines for COVID-19 antibody testing in clinical and public health settings updated Mar. 17, 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.
Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019: evaluation and testing. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html.
World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans page. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93.
Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17:647–9.
Huang Y, Sun H, Yu H, Li S, Zheng Q, Xia N. Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Antib Ther. 2020;3:285–99.
Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H, et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021;594:553–9.
Wood SN. Thin plate regression splines: thin plate regression splines. J R Stat Soc Ser B Stat Methodol. 2003;65:95–114.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. https://www.R-project.org/.
Bürkner P-C. brms: an R package for Bayesian multilevel models using Stan. J Stat Softw. 2017. https://doi.org/10.18637/jss.v080.i01.
Feng Y, Chen J, Yao T, Chang Y, Li X, Xing R, et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial. Infect Dis Poverty. 2021;10(1):138.
Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2021;40(1):26–34.
Alqassieh R, Suleiman A, Abu-Halaweh S, Santarisi A, Shatnawi O, Shdaifat L, et al. Pfizer-BioNTech and Sinopharm: a comparative study on post-vaccination antibody titers. Vaccines. 2021;9:1223.
Fu Y, Chen F, Cui L, Zhao Y, Zhang H, Fu S, et al. Immunological analysis of people in Northeast China after SARS-CoV-2 inactivated vaccine injection. Vaccines. 2021;9:1028.
Vályi-Nagy I, Matula Z, Gönczi M, Tasnády S, Bekő G, Réti M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. GeroScience. 2021;43:2321–31.
Lijeskić O, Klun I, Stamenov Djaković M, Gligorić N, Štajner T, Srbljanović J, et al. Prospective cohort study of the kinetics of specific antibodies to SARS-CoV-2 infection and to four SARS-CoV-2 vaccines available in Serbia, and vaccine effectiveness: a 3-month interim report. Vaccines. 2021;9:1031.
Dashdorj NJ, Wirz OF, Röltgen K, Haraguchi E, Buzzanco AS, Sibai M, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host Microbe. 2021;29(12):1738–43.
Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Jayathilaka D, et al. Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. Preprint, medRxiv. 2021. https://doi.org/10.1101/2021.07.15.21260621.
Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe A, et al. Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals. Preprint, medRxiv. 2021. https://doi.org/10.1101/2021.10.14.21265030.
Li X-N, Huang Y, Wang W, Jing Q-L, Zhang C-H, Qin P-Z, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. Emerg Microbes Infect. 2021;10:1751–9.
Macchia A, Ferrante D, Angeleri P, Biscayart C, Mariani J, Esteban S, et al. Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Netw Open. 2021;4:e2130800.
Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.11.011.